Wednesday, November 18, 2026
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Comprehensive Genomic Profiling Increases Actionable Mutation Detection in Advanced Solid Tumors

November 18, 2026
in Cancer
Juliet Wilcox
By Juliet Wilcox Scienmag Editorial Profile - Human Genetics
Reading Time: 6 mins read
0
Comprehensive Genomic Profiling Increases Actionable Mutation Detection in Advanced Solid Tumors

Comprehensive Genomic Profiling Increases Actionable Mutation Detection in Advanced Solid Tumors

65
SHARES
587
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

A retrospective real-world study has demonstrated that comprehensive genomic profiling (CGP) is more effective than single-gene or small-panel (SP) testing in identifying actionable genetic alterations for patients diagnosed with advanced or metastatic solid tumors. The findings, published in 2026, indicate that CGP testing, which utilizes next-generation sequencing, detects significantly higher rates of clinically actionable biomarkers—specifically those recognized by the OncoKB precision oncology knowledge base—across a diverse range of cancer types, including non-small cell lung cancer (NSCLC), colorectal cancer, prostate cancer, breast cancer, and melanoma. By comparing these two diagnostic methods within a broad clinical dataset, the research provides a basis for evaluating the potential benefits of expanding CGP coverage and adoption in routine clinical practice to improve targeted treatment opportunities for patients with advanced disease.

Genetic testing has become an essential component of modern oncology, as approximately 200 genomic biomarkers have been identified that guide prognosis and the selection of targeted therapies. Traditionally, clinicians have relied on single-gene or small-panel hotspot testing to detect point mutations, insertions, or deletions. While these methods are often accurate and routinely performed in hospital settings, they are limited by their narrow scope, as they do not assess a large number of genes simultaneously and may fail to identify clinically relevant alterations, rearrangements, or pan-tumor biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB). In contrast, CGP employs next-generation sequencing to simultaneously analyze multiple genomic alterations across a broad array of genes. This capability allows for a more comprehensive characterization of mutation patterns within established cancer pathways, potentially informing treatment decisions, prognosis, and long-term monitoring.

To investigate the comparative clinical utility of these testing strategies, researchers derived a retrospective cohort from an integrated electronic medical record (EMR) database. This database, which covers more than 160 million patients across 30 health systems in the United States, allowed the team to analyze patient data spanning from 2018 to 2022. The study included adult patients diagnosed with advanced or metastatic solid tumors who received either a CGP or an SP test during the index period. The final analysis set consisted of 406 patients, split evenly between 202 CGP-tested patients and 204 SP-tested patients. To ensure a robust comparison and minimize selection bias, the researchers employed propensity score matching using nearest neighbor matching without replacement, followed by inverse probability of treatment weighting (IPTW) to balance baseline characteristics, including age, sex, geographic region, tumor type, and Charlson Comorbidity Index score.

The study’s primary objective was to assess OncoKB-derived treatment actionability. OncoKB acts as a precision oncology knowledge base that categorizes cancer gene alterations based on evidence-based clinical actionability. The researchers were particularly interested in OncoKB levels 1, 2, and R1, which denote biomarkers predictive of response to FDA-approved drugs, standard-of-care biomarkers recommended by professional guidelines, and markers predictive of resistance to specific therapies, respectively. Clinical actionability was defined by the extent to which the gene, alteration, and cancer type matched OncoKB recommendations, either fully or partially. While pan-tumor markers like MSI and TMB were captured when reported in medical notes, PD-L1 expression was evaluated separately and excluded from the primary OncoKB-based endpoint, providing a focused analysis on actionable mutation detection within the specified levels.

The results of the analysis revealed that patients in the CGP-tested cohort had a significantly higher percentage of actionable findings compared to the SP-tested group. Specifically, 55.9% of CGP-tested patients demonstrated a positive biomarker result eligible for OncoKB level 1, 2, or R1, compared to 41.2% in the SP-tested cohort, resulting in a weighted actionability ratio of 1.5. A deeper analysis showed that 50% of the CGP group met OncoKB level 1 criteria compared to only 31.4% in the SP group, yielding an actionability ratio of 1.76. Furthermore, CGP-tested patients were more than twice as likely to have OncoKB level 2 eligibility, with 22.8% of the CGP group compared to 10.3% in the SP group. There was no statistically significant difference between the cohorts regarding the detection of level R1 eligibility, but the breadth of biomarkers identified by CGP was notably wider, extending to genes less frequently captured in smaller panels.

Beyond the primary OncoKB metrics, the researchers analyzed the distribution of biomarkers across different cancer types to assess the clinical coverage provided by CGP. While frequently observed actionable alterations such as KRAS, BRAF, and EGFR were identified at similar frequencies in both testing cohorts, CGP demonstrated a clear advantage by identifying additional actionable alterations in a broader range of genes, such as ERBB2, PIK3CA, and DNA damage repair genes like BRCA2. This consistent pattern across tumor-specific analyses suggests that while small panels might capture the most common drivers, they likely miss a wider spectrum of clinically relevant targets. This comprehensive detection profile is particularly valuable in the context of advanced cancers, where multiple potential therapeutic pathways may be involved and identifying all eligible targets can significantly expand treatment options or clinical trial enrollment opportunities.

The study highlights a critical gap in current clinical practice, where the adoption of CGP is often limited by higher costs, perceived lack of clinical utility among some payers, and inconsistent insurance coverage. Many oncologists, particularly those in community settings who manage a wide variety of cancer cases, may struggle to remain updated on which specific gene panels are appropriate for each cancer type. Furthermore, concerns regarding insurance delays and the risk of denial often lead to the use of smaller, less comprehensive panels, which may result in suboptimal treatment pathways or the need for repeat testing. The researchers suggest that the routine use of CGP for metastatic cancer could reduce these testing inefficiencies by providing a single, comprehensive diagnostic assessment at the onset of treatment planning, thereby avoiding the time and effort spent validating and marketing new, individualized panels for each emerging data point on specific mutations.

Despite the findings, the study acknowledges several limitations inherent in the use of retrospective EMR data. Because the molecular assays—including their gene content, depth of coverage, and bioinformatic pipelines—were not standardized across the patient population, the researchers were forced to define testing methods operationally through billing codes and manual chart abstraction. This approach reflects how genomic data is captured in EMR systems rather than the technical specifications of the assays themselves. Additionally, the study faced challenges with missing data for certain baseline variables, such as race, ethnicity, and pathology, which limited the ability to perform demographic subgroup analyses. The relatively small sample size also restricted the researchers’ ability to detect reliable temporal trends or establish the generalizability of findings to less-represented tumor types within the cohort.

A critical limitation noted by the authors is that the dataset lacked specific clinical outcomes, such as progression-free survival or overall survival, as well as detailed cost data. As such, the study could not directly measure whether the increased detection of actionable biomarkers translated into improved survival for patients or if it represented a clear economic value compared to SP testing. Future research will need to incorporate these longitudinal clinical and economic outcomes to fully validate the real-world impact of CGP adoption. Nevertheless, the study’s reliance on EMR data provides a strong foundation by capturing a broader, more representative patient population than what is typically seen in randomized clinical trials or single-institution research, validating its findings through a transparent and iterative curation protocol.

The authors emphasize that the goal of this study is not to suggest that small-panel testing is entirely obsolete. There remain specific clinical scenarios—such as when clinical presentation strongly suggests a high pretest probability of a specific actionable mutation, such as EGFR mutations in never-smoking East-Asian patients—where rapid SP testing can provide timely results to guide immediate treatment decisions. Furthermore, SP testing is often preferred in situations where tissue quantity is severely limited and a specific, high-probability target must be prioritized. Therefore, the decision between CGP and SP should be individualized based on the clinical context, urgency of treatment, tissue availability, and the anticipated likelihood of identifying actionable alterations beyond the standard small-panel targets. Ultimately, the study concludes that CGP represents the next logical step in the management of advanced and metastatic cancers, offering a more precise, comprehensive approach that, with expanded reimbursement and coverage, could connect significantly more patients with targeted therapies.

Subject of Research: Clinical comparative analysis of genomic profiling methods in advanced cancer management.

Article Title: Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels

Article References: Spin, P., Bapat, B., Moretz, C., Dumanois, R., Gilligan, A. M., Shokoohi, M., Borgundvaag, E., Fox, J., Bifulco, C., & Bartlett, D. (2026). Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels. Oncology and Therapy, 14(3), 1011-1024. https://doi.org/10.1007/s40487-026-00453-8

Image Credits: AI Generated

DOI: 10.1007/s40487-026-00453-8

Keywords: Comprehensive Genomic Profiling, Oncology, Genomic Testing, Solid Tumors, OncoKB, Targeted Therapy, Precision Medicine, Next-Generation Sequencing, Cancer Research, Real-World Evidence, NSCLC, Colorectal Cancer, Prostate Cancer, Breast Cancer, Melanoma, Clinical Actionability, Genetic Biomarkers

Cite Scienmag News

Juliet Wilcox. (November 18, 2026). Comprehensive Genomic Profiling Increases Actionable Mutation Detection in Advanced Solid Tumors. Scienmag. https://scienmag.com/comprehensive-genomic-profiling-increases-actionable-mutation-detection-in-advanced-solid-tumors/

Juliet Wilcox. "Comprehensive Genomic Profiling Increases Actionable Mutation Detection in Advanced Solid Tumors." Scienmag, 18 November 2026, https://scienmag.com/comprehensive-genomic-profiling-increases-actionable-mutation-detection-in-advanced-solid-tumors/. Accessed 18 November 2026.

Juliet Wilcox. "Comprehensive Genomic Profiling Increases Actionable Mutation Detection in Advanced Solid Tumors." Scienmag. November 18, 2026. https://scienmag.com/comprehensive-genomic-profiling-increases-actionable-mutation-detection-in-advanced-solid-tumors/

Tags: breast cancercancer researchclinical actionabilityColorectal cancercomprehensive genomic profilinggenetic biomarkersgenomic testingmelanomanext-generation sequencingNSCLCOncoKBoncologyPrecision medicineprostate cancerReal-world evidencesolid tumorsTargeted therapy
Share26Tweet16
Previous Post

Engineered Bacterial Injection Systems Deliver Functional Proteins into Targeted Plant Cells

Next Post

Daily Eating Intake Variability Linked to Higher Insulin Resistance Indices in Women

Related Posts

Pedigree Analysis Expands Known Neoplasm Spectrum in Li-Fraumeni Syndrome
Cancer

Pedigree Analysis Expands Known Neoplasm Spectrum in Li-Fraumeni Syndrome

November 18, 2026
Neuropeptide CGRP Signaling Drives Cervical Cancer Progression Through Endothelial Angiogenesis
Cancer

Neuropeptide CGRP Signaling Drives Cervical Cancer Progression Through Endothelial Angiogenesis

November 18, 2026
Cancer Cells Neutralise Toxic Formaldehyde and Resist Ferroptosis Through Coordinated Defences
Cancer

Cancer Cells Neutralise Toxic Formaldehyde and Resist Ferroptosis Through Coordinated Defences

November 18, 2026
Investigational Regimens Shift Myeloproliferative Neoplasm Care Toward Biologically Informed Targets
Cancer

Investigational Regimens Shift Myeloproliferative Neoplasm Care Toward Biologically Informed Targets

November 18, 2026
Zanubrutinib Associated With Improved Real-World Outcomes in Older CLL Patients
Cancer

Zanubrutinib Associated With Improved Real-World Outcomes in Older CLL Patients

November 18, 2026
Peptide Vaccine Reduces Bladder Tumour Burden Up to 53 Percent in Mice
Cancer

Peptide Vaccine Reduces Bladder Tumour Burden Up to 53 Percent in Mice

November 18, 2026
Next Post
Daily Eating Intake Variability Linked to Higher Insulin Resistance Indices in Women

Daily Eating Intake Variability Linked to Higher Insulin Resistance Indices in Women

  • Mothers who receive childcare support from maternal grandparents show more optimized

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27656 shares
    Share 11059 Tweet 6912
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    1061 shares
    Share 424 Tweet 265
  • Bee body mass, pathogens and local climate influence heat tolerance

    682 shares
    Share 273 Tweet 171
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    546 shares
    Share 218 Tweet 137
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    531 shares
    Share 212 Tweet 133
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Neolithic Shellfish Harvesting at Barrosinha Remained Stable Without Signs of Overexploitation
  • Regularized Ensemble Method Improves Polygenic Risk Prediction Using GWAS Summary Statistics
  • Zero-Shot Spillover Denoising Algorithm Cleans High-Dimensional Multiplexed Tissue Imaging Datasets
  • Immature Hippocampal Neurons Help Mice Distinguish Competing Social Memories

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Biotechnology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Editorial Policy
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Science News
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,151 other subscribers

© 2026 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2026 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading